Status:
COMPLETED
Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain
Lead Sponsor:
Pfizer
Conditions:
Pain, Postoperative
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To validate the morphine-sparing effect and safety of parecoxib administered intravenously for the treatment of Chinese subjects with postoperative pain following gynecological or orthopedic surgery.
Eligibility Criteria
Inclusion
- Undergo gynecological or orthopedic surgery under epidural anesthesia
Exclusion
- A previous history of intolerance or hypersensitivity to any NSAID, cyclooxygenase-2 selective inhibitors, sulphonamides, or any of the excipients of parecoxib.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00143169
Start Date
September 1 2004
End Date
June 1 2005
Last Update
April 15 2008
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Guangzhou, Guangdong, China, 510080
2
Pfizer Investigational Site
Shenyang, Liaoning, China, 110001
3
Pfizer Investigational Site
Qingdao, Shandong, China, 266011
4
Pfizer Investigational Site
Beijing, China, 100020